LLS2 is a novel potent Galectin-1 (Gal1) inhibitor that decreases membrane-associated H-Ras and K-Ras and contributed to the suppression of pErk pathway.

LLS30 is a potent, allosteric Galectin-1 (Gal-1) inhibitor, inhibits AR negative cells PC3, DU145, and AR positive cells, 22RV1 and CWR-R1 cells with IC50 of 10.4 μM, 5.3 μM, 3.3 μM and 5.9 μM, respectively.

LLY-2707 (LLY 2707, LLY2707) is a novel potent, selective, nonsteroidal glucocorticoid receptor antagonist with Ki of 2.13 nM.

LLY-283 (LLY283) is a potent, selective inhibitor of arginine methyltransferase 5 (PRMT5) with IC50 of 22 nM.

LMD-009 (LMD 009, LMD009) is a potent, selective, nonpeptide CCR8 agonist that stimulates CCR8-mediated chemotaxis, inositol phosphate accumulation and calcium release with EC50 of 11-87 nM.

LMD-A (CCR8 antagonist LMD-A) is a highly potent, small molecule antagonist of chemokine receptor CCR8 with EC50 of 2.5 nM.

LML134 (compound 18b) is an orally active and high selective Histamine 3 receptor (H3R) inverse agonist with Kis of 0.3 nM and 12 nM for hH3R cAMP and hH3R bdg. LML134 penetrates the brain rapidly, leading to high H3R occupancy, and disengages its target with a fast kinetic profile. LML134 has the potential for excessive sleep disorders[1].

LMT-28 (LMT28) is a specific blocker of IL-6 signaling via inhibits IL-6Rβ (gp130) with IC50 of 5.9 uM (IL-6–induced luciferase activity), selectively inhibits IL-6–induced phosphorylation of STAT3, JAK2, and gp130.

LN-1-255 is a 6-alkylidene-2'-substituted penicillin sulfone that acts as an effective beta-lactamase inhibitor.

Loganetin is a non-toxic natural product that may be applied in the antibacterial drug development for treating multidrug-resistant Gram negative infections.

LOM612 is a potent activator of FOXO nuclear translocation, with an EC50 value of 1.5 μM in cells.

Lometrexol is a tight-binding antifolate inhibitor of the purine de novo enzyme glycinamide ribonucleotide formyltransferase (GARFT), was the first GARFT inhibitor to be investigated clinically.

Lopixibat chloride (LUM-001, HP-625) is a potent, selectiove, oral inhibitor of sodium bile acid cotransporter and Ileal bile acid transporter (IBAT)..

Lorcaserin (APD-356)is a weight-loss drug developed by Arena Pharmaceuticals. It has serotonergic properties and acts as an anorectic.

L-ornithine has an antifatigue effect by increasing the efficiency of energy consumption and promoting the excretion of ammonia. It is one of the key reactants in the urea cycle.

Losmapimod (GW856553X) is a selective, potent, and orally active p38 MAPK inhibitor with pKi of 8.1 and 7.6 for p38α and p38β, respectively. Phase 3.

LP99 is the first potent and selective BRD7/9 bromodomain inhibitor with Kd of 99 nM for BRD9.

LR-90 is an advanced glycation end product (AGE) inhibitor, inhibits inflammatory responses in human monocytes. LR-90 is also used in the research of diabetic animal model.

LRE1 is a specific and allosteric inhibitor of soluble adenylyl cyclase.

LSD1 inhibitor 24 is a novel potent, selective lysine-specific demethylase 1 (LSD1) inhibitor with IC50 of 1 nM, induces CD11b expression in THP-1 cells with EC50 of 8 nM.

LSD1 inhibitor-1 is a bisguanidine polyamine analogue that exhibits noncompetitive and specific LSD1 inhibition, with 14.1% remaining LSD1 activity at 10 uM in vitro.

ORY-1001 dihydrochloride (RG-6016, Ladademstat) is a highly potent, selective inhibitor of lysine-specific demethylase KDM1A (LSD1) with IC50 of 18 nM, displays high selectivity for KDM1A over other FAD-containing monoamine oxidases.